Publications by authors named "T Lezhava"
Article Synopsis
- The research focused on the frequency of VKROC1 and CYP2C9 gene variants in both healthy individuals and thrombosis patients within the Abkhazian population, examining their impact on warfarin treatment.
- Results showed that healthy donors had a higher frequency of the heterozygous VKROC1 genotype compared to thrombosis patients, highlighting potential genetic predispositions to thrombotic conditions.
- Significant differences were observed in the CYP2C9 gene variants, with the wild-type genotype more prevalent in healthy individuals than in thrombotic patients, indicating a possible link between these gene variants and susceptibility to thrombosis.
In the present study, on the one hand, the epigenetic modification of condensed "old" chromatin was determined, and on the other hand, the influence of peptide bioregulators (Ala-Glu-Asp-Gly-Epitalon; Lys-Glu-Asp-Ala-Livagen; Ala-Glu-Asp-Pro - Cortagen and Lys-Glu - Vilon) on condensed chromatin in lymphocytes from old individuals. Were used molecular-cytogenetic methods: differential scanning calorimetry; activity of ribosomal genes of acrocentric chromosome satellite stalks-NORs; polymorphism of structural pericentromeric C-heterochromatin; variability of the facultative heterochromatin (sister chromatid exchanges - SCE) in the culture of lymphocytes from 75-88-year-old individuals. The analysis of results shows the chromosome progressive heterochromatinization (condensation of eu - and heterochromatin regions) occur in aging.
View Article and Find Full Text PDFThe article presents data on the genome status of pregnant women in different trimesters of pregnancy, during the normal course of pregnancy. The variability of ribosomal cystone activation as well as the variability of genome stability (frequencies of chromosomal aberrations and fragile sites) in different trimesters of pregnancy have been studied to detect genome-specific functional variability for each trimester.It was found that the level of genome stability determined by the frequency of chromosomal structural disorders and fragile sites in all three trimesters of pregnancy did not differ significantly from similar rates for non-pregnant healthy women.
View Article and Find Full Text PDFArticle Synopsis
- Acalabrutinib is a selective and effective BTK inhibitor used for treating various B-cell cancers, analyzed through safety data from 1,040 patients across nine clinical studies.
- Key adverse events included headache (38%), diarrhea (37%), and upper respiratory infections (22%), with serious adverse events reported in 39% of patients, largely pneumonia.
- The study confirmed acalabrutinib's tolerability and suggested it can be a viable long-term treatment option for patients with mature B-cell malignancies without revealing new late toxicities.
Following the completion of the Human Genome Project, the strategic direction of modern genetics has moved toward functional genomics, to explore the functions of non-coding regions of DNA. These non-coding regions are localized in heterochromatin. The functions of heterochromatin largely remain unclear.
View Article and Find Full Text PDF